Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion (~ USD 184 million). The proceeds will fund global multi‑center clinical development of a novel HIV integrase inhibitor (RMB 767 million / USD 111 million), consolidate control of Nanda Pharmaceutical (RMB 130 million / USD 18 million), and supplement working capital (RMB 380 million / USD 55 million).
Financing Allocation
Use of Funds
Amount
Percentage
Strategic Purpose
HIV Integrase Inhibitor Development
RMB 767 M (USD 111 M)
60%
Global multi‑center trials (China + US)
Nanda Pharmaceutical Acquisition
RMB 130 M (USD 18 M)
10%
Consolidate control; deepen human protein expertise
Working Capital
RMB 380 M (USD 55 M)
30%
Core R&D + commercial rollout
Strategic Priorities
1. HIV Integrase Inhibitor – Global Development
Parameter
Detail
Drug Class
Novel HIV integrase inhibitor
Clinical Stage
Global multi‑center trials
Core Markets
China + United States
Investment
RMB 767 million (~ 60% of total raise)
Strategic Goal
First‑in‑class or best‑in‑class HIV therapy addressing resistance and long‑acting needs
2. Nanda Pharmaceutical Consolidation
Parameter
Detail
Transaction
Additional share acquisition
Investment
RMB 130 million
Strategic Rationale
Strengthen control; leverage human protein synergies for new drug R&D
Platform Value
Human protein expertise supports biologics and complex formulation development
3. Working Capital & Commercialization
Parameter
Detail
Allocation
RMB 380 million
Purpose
Core research continuity + commercial infrastructure build‑out
Strategic Implications
HIV Innovation Focus: The 60% allocation to HIV integrase inhibitor signals Aidea’s strategic bet on next‑generation antiretroviral therapy—potentially addressing resistance mutations, long‑acting formulations, or improved safety profiles vs. existing integrase inhibitors (dolutegravir, bictegravir).
Global Clinical Ambition:China + US multi‑center trials position Aidea for simultaneous regulatory submissions and global partnership attractiveness—rare for domestic Chinese infectious disease developers.
Nanda Synergies:Human protein platform consolidation enables biologics manufacturing capabilities and complex formulation expertise, supporting HIV drug delivery innovation (e.g., long‑acting injectables).
Capital Efficiency: The three‑pronged allocation balances high‑risk R&D (HIV), strategic M&A (Nanda), and operational runway (working capital)—demonstrating disciplined capital deployment.
Financing supports HIV lead asset while Nanda integration enables platform expansion into other infectious diseases or protein therapeutics
Forward‑Looking Statements This brief contains forward‑looking statements regarding HIV integrase inhibitor Phase I/II initiation, Nanda integration synergies, and global regulatory pathway execution. Actual results may differ due to risks including competitive GSK/Gilead advancement, HIV resistance evolution, and manufacturing scale‑up challenges for novel formulations.-Fineline Info & Tech
By Fineline Cube 